Mersana Therapeutics Inc logo

MRSN

Mersana Therapeutics Inc

$7.4

Earnings Summary

Revenue
$2.04Mn
Net Profits
$-47.26Mn
Net Profit Margins
-2321.12%

Highlights

Revenue:

Mersana Therapeutics Inc’s revenue jumped 18409.09% since last year same period to $2.04Mn in the Q1 2022. On a quarterly growth basis, Mersana Therapeutics Inc has generated 18409.09% jump in its revenue since last 3-months.

Net Profits:

Mersana Therapeutics Inc’s net profit fell -36.22% since last year same period to $-47.26Mn in the Q1 2022. On a quarterly growth basis, Mersana Therapeutics Inc has generated 3.52% jump in its net profits since last 3-months.

Net Profit Margins:

Mersana Therapeutics Inc’s net profit margin jumped 99.26% since last year same period to -2321.12% in the Q1 2022. On a quarterly growth basis, Mersana Therapeutics Inc has generated 99.48% jump in its net profit margins since last 3-months.

Earnings per share (EPS) Estimates

Earnings per share (EPS) estimates of the Mersana Therapeutics Inc post its latest quarter earnings

EPS Estimate Current Quarter
-0.52
EPS Estimate Current Year
-0.52

Highlights

EPS Estimate Current Quarter:

Mersana Therapeutics Inc’s earning per share (EPS) estimates for the current quarter stand at -0.52 - a -62.5% fall from last quarter’s estimates.

EPS Estimate Current Year:

Mersana Therapeutics Inc’s earning per share (EPS) estimates for the current year stand at -0.52.

Key Ratios

Key ratios of the Mersana Therapeutics Inc post its Q1 2022 earnings

Earning Per Share (EPS)
-0.59
Return on Assets (ROA)
-0.47
Return on Equity (ROE)
-1.18
Dividend Per Share (DPS)
0

Highlights

Earning Per Share (EPS):

Mersana Therapeutics Inc’s earning per share (EPS) fell -18% since last year same period to -0.59 in the Q1 2022. This indicates that the Mersana Therapeutics Inc has generated -18% annual rate of fall in its earning per share (EPS) in the last 4 quarters.

Return on Assets (ROA):

Return on assets (ROA) indicates the profitability of the company in relation to its total assets. This ratio tells the financial health of the company. The higher the ROA, the better the company’s financial health. If any company has a ROA in the range of 5% to 20% - it is generally considered good. ROA above 20% is generally considered excellent. Mersana Therapeutics Inc’s return on assets (ROA) stands at -0.47.

Earning Per Share (EPS):

The Return On Equity ratio indicates a company’s ability to turn equity capital received from shareholders into profits. ROE highlights the efficiency of equity capital in running the business. Generally, a return on equity in double digits is considered good. Mersana Therapeutics Inc’s return on equity (ROE) stands at -1.18.

Dividend Per Share (DPS):

Mersana Therapeutics Inc declared 0 dividend per share during the earnings announcement for Q1 2022.

Earnings Calendar

Earnings DateEstimated EPSReported EPSSurprise %
2022-05-09
-0.32
-0.59
-84.37%

Company Information

Mersana Therapeutics is a clinical-stage biopharmaceutical company using its differentiated and proprietary ADC platforms to rapidly develop novel ADCs with optimal efficacy, safety and tolerability to meaningfully improve the lives of people fighting cancer. Mersana's lead product candidate, upifitamab rilsodotin (UpRi), is a Dolaflexin ADC targeting NaPi2b and is in the expansion portion of a Phase 1 proof-of-concept clinical study in patients with ovarian cancer and NSCLC adenocarcinoma. XMT-1592, Mersana's second ADC product candidate targeting NaPi2b-expressing tumors, was created using Mersana's customizable and homogeneous Dolasynthen platform and is in the dose escalation portion of a Phase 1 proof-of-concept clinical study. The Company's early-stage programs include XMT-1660, a Dolasynthen ADC targeting B7-H4, as well as XMT-2056, a STING-agonist ADC developed using the Company's Immunosynthen platform. In addition, multiple partners are using Mersana's Dolaflexin platform to advance their ADC pipelines.

Organisation
Mersana Therapeutics Inc
Headquarters
Cambridge, Massachusetts, US
Employees
110
Industry
Health Technology
CEO
Anna Protopapas